Glucose News and Research

RSS

White paper describes health and economic burden of diabetes on Americans

PositiveID Corporation announced today that it has published a white paper entitled “Fixing the Black Hole in Diabetes Management,” which describes the health and economic burden of diabetes on Americans and our economy.

19 Mar 2010

Lifestyle improvements and new treatments for diabetes and cardiovascular disease needed

Treatment with the anti-hypertensive drug valsartan (Diovan) led to a modest reduction in the development of type 2 diabetes but did not significantly reduce cardiovascular events in patients with impaired glucose tolerance, according to researchers at Duke University Medical Center and the University of Oxford. They jointly reported results at the American College of Cardiology meeting today from the world's first study designed to find ways to control the progression to diabetes and cardiovascular disease in people at risk.

19 Mar 2010

Study reveals higher-than-normal blood levels of fructose in pancreatic cancer patients

Patients with pancreatic cancer have higher-than-normal blood levels of the refined sugar fructose, according to a recent study in the journal Pancreas, official journal of the American Pancreatic Association and the Japan Pancreas Society. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.

19 Mar 2010

Diabetes patients who have lower tendency to reach out to others have higher mortality rate: Study

Mistrust can exact a high toll. Being overly cautious or dismissive in relating to people, researchers are learning, may shorten the lives of people with diabetes.

19 Mar 2010

NexACT technology demonstrates ability to deliver Taxol subcutaneously

NexMed, Inc., a specialty CRO and a developer of products based on the NexACT® technology, today announced that pre-clinical results from the research and development group at its Bio-Quant subsidiary have successfully demonstrated the ability of the NexACT technology to deliver insulin and other large molecule drugs such as Taxol subcutaneously, in a depot-like fashion (or slow release) over a 24 hour period from a single injection.

18 Mar 2010

Phase 2a clinical trial results of CPEX Pharmaceuticals' Nasulin insulin

CPEX Pharmaceuticals Inc. today reported preliminary results related to its Phase 2a proof-of-concept clinical trial of the Company’s nasal insulin product, Nasulin™. The study was designed to evaluate the efficacy and safety of Nasulin versus placebo over a 6-week treatment period in subjects with Type 2 diabetes who were being treated with basal insulin and oral anti-diabetes agents.

18 Mar 2010

FDA approves Medtronic's MiniMed Paradigm integrated diabetes management system

Medtronic, Inc. today announced it has received U.S. Food and Drug Administration (FDA) approval for the MiniMed Paradigm® REAL-Time Revel™ System, the next generation of the industry’s only integrated diabetes management system (insulin pump therapy, continuous glucose monitoring (CGM) and diabetes therapy management software).

17 Mar 2010

Hi-maize whole grain corn flour and Hi-maize resistant starch increase satiety

A University of Toronto (Toronto, Canada) research team, led by G. Harvey Anderson, Ph.D., just published results of a new study in the American Journal of Clinical Nutrition, showing that the quantity of resistant starch in foods correlates with blood glucose response and reduced food intake after two hours.

16 Mar 2010

MIF exhibits potential as viable therapeutic target for Type 2 diabetes

An experimental oral drug has lowered blood sugar levels and inflammation in mice with Type 2 diabetes, suggesting that the medication could someday be added to the arsenal of drugs used by millions of Americans with this disease, according to new research.

16 Mar 2010

Arthritis drug could be useful for treating patients with type 2 diabetes

Clinical studies of a generic drug called salsalate, widely prescribed for arthritis, now provide early promising results that it may be useful for the treatment of patients with type 2 diabetes as well.

16 Mar 2010

Roche Diagnostics named sole source supplier for Premier's blood glucose monitoring devices

Roche Diagnostics announced today that it has been awarded contracts for blood glucose monitoring and clinical chemistry/immunoassay lab analyzers from Premier Purchasing Partners, L.P., Inc., the group purchasing unit of Premier, Inc. Roche was also named the sole source supplier for blood glucose in Premier's exclusive ASCEND supply chain performance program.

From Roche Sequencing and Life Science 16 Mar 2010

Publix Pharmacies launches first phase of new diabetes management system

Today Publix Pharmacies launched the first phase of a new diabetes management system. The program is a multi-faceted program established to assist customers and associates living with diabetes in managing their medication, compliance, monitoring, education, nutrition and exercise.

16 Mar 2010

Study: Hypoglycemia patients have mortality rate of 36.6%

In a study published in the March issue of Mayo Clinic Proceedings, researchers report that they have found a link between mild to moderate hypoglycemia (low blood sugar) and mortality in critically ill patients.

16 Mar 2010

High ABI may indicate risk for future heart attacks

The prevalence of abnormal ankle-brachial index (ABI) test results among individuals tested for peripheral arterial disease (PAD)—and who are not considered at high risk of a coronary heart event by Framingham-based risk factors—is high and provides another way to identify those who may be at risk for future heart attacks, say researchers at the Society of Interventional Radiology's 35th Annual Scientific Meeting in Tampa, Fla.

15 Mar 2010

Valsartan delays progression to type 2 diabetes in IGT patients: NAVIGATOR study

Results from a landmark study involving more than 9,000 people showed that the high blood pressure medicine valsartan delayed progression to type 2 diabetes in patients with cardiovascular disease or risk factors and impaired glucose tolerance (IGT), a common pre-diabetic condition.

15 Mar 2010

VEGF-B protein can control levels of FATPs in vascular wall: Study

A new study from the Swedish medical university Karolinska Institutet shows that the blood vessels and muscles of the heart can regulate the uptake of fatty acids that we ingest through meat, milk products and other food. The researchers behind the study have also identified the way in which regulation is governed by the muscles themselves.

15 Mar 2010

Nanoparticles provide a targeted version of photothermal therapy for cancer

In a lecture he delivered in 1906, the German physician Paul Ehrlich coined the term Zuberkugel, or "magic bullet," as shorthand for a highly targeted medical treatment.

15 Mar 2010

Obese type 2 diabetics carry mitochondrial proteins that reduce response to physical exercise

Diet and aerobic exercise are highly effective for the treatment of type 2 diabetes, but not for obese subjects that have developed the disease when very young. A study at the Institute for Research in Biomedicine and Trinity College in Dublin demonstrates that obese subjects between 18 and 25 years of age carry mitochondrial proteins and genes that work abnormally and that these anomalies contribute to generating insulin resistance and a reduced response to physical exercise.

15 Mar 2010

Discovery of MiR-451 molecule may serve as a biomarker for brain tumor

Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

15 Mar 2010

XOMA initiates Phase 2 clinical trial of XOMA 052 in Type 1 diabetes patients

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, announced the initiation of a Phase 2 clinical trial of XOMA 052, its antibody to interleukin-1 beta (IL-1 beta), in Type 1 diabetes patients. Funding for the trial is being provided by the Juvenile Diabetes Research Foundation International, the largest patient advocacy organization of Type 1 diabetes research worldwide.

12 Mar 2010